| Article Access Statistics | | | Viewed | 442 | | | Printed | 27 | | | Emailed | 0 | | | PDF Downloaded | 41 | | | Comments | [Add] | | |
|
Click on image for details.
|
|
| ARTICLE |
|
|
|
|
|
| Year : 1998 | Volume
: 40
| Issue : 3 | Page : 247-253 |
Risperidone in Indian Patients with Schizophrenia
AK Agarwal1, V.S.P Bashyam2, SM Channabasavanna3, HS Dhavale4, M. A. M Khan5, Sumant Khanna6, PV Pradhan7, M Katiyar8, R Rajkumar9, Faiz R Niazi10, RK Jalali11, R Gowrishankar12, SK Mishra13, OP Sood14
1 Professor & Head, Department of Psychiatry, King George's Medical College, Lucknow, India
2 Director, Institute of Mental Health, Chennai, India
3 Director National Institute of Mental Health & Neuro Sciences, Bangalore, India
4 Professor & Head, Department of Psychiatry, BYL Nair Charitable Hospital, Mumbai, India
5 Professor, Department of Psychiatry, Deccan College of Medical Sciences, Hyderabad, India
6 Additional Professor, National Institute of Mental Health & Neuro Sciences, Bangalore, India
7 Hon. Professor, Department of Psychiatry. Seth GS Medical College, & KEM Hospital, Mumbai, India
8 Associate Professor, Department of Psychiatry, King George's Medical College, Lucknow, India
9 Assistant Professor of Psychiatry, Institute of Mental Health, Chennai, India
10 Clinical Research Scientist, Ranbaxy Laboratories Ltd., Gurgaon, India
11 Clinical Research Physician, Ranbaxy Laboratories Ltd., Gurgaon, India
12 Head-Clinical Research, Ranbaxy Laboratories Ltd., Gurgaon, India
13 Assistant Director, Medical Affairs & Clinical Research, Ranbaxy Laboratories Ltd., Gurgaon, India
14 Vice President, Medical Affairs & Clinical Research, Ranbaxy Laboratories Ltd., Gurgaon, India
Correspondence Address:
A K Agarwal
Professor & Head, Department of Psychiatry, King George's Medical College, Lucknow
India
 Source of Support: None, Conflict of Interest: None  | Check |
PMID: 21494480 
Conventional antipsychotic agents are not effective against negative symptoms of schizophrenia and are also noted for their extrapyramidal side effects. Risperidone is a noval antipsychotic agent whose dual antagonism of dopamine and serotonin receptors is believed to underlie its efficacy against negative symptoms and the low incidence of extrapyramidal side effects. An open, non-comparative study of seven weeks duration was performed to evaluate risperidone in the treatment of schizophrenia in Indian patients. Previous antipsychotic therapy was discontinued for a week before risperidone therapy was initiated. At the end of six weeks of risperidone therapy, clinical improvement (≥ 20% reduction in total score on positive and negative syndrome scale for schizophrenia (PANSS;; was shown by 128 (87.7%) of the 146 evaluable patients. Statistically significant reduction (p <0.05) occurred in the total score of this scale and in the subscale scores for positive, negative and general psychopathology symptoms and in the clinical global impression severity score. The number of patients with adverse experiences were 108 (65.5%) at baseline and 120 (72.7%) at the end of risperidone therapy. Extrapyramidal symptoms, seen in 65 (39.4%) patients compared to 22 (13.3%) patients at baseline, were largely mild to moderate in intensity.
[PDF]*
|
